Follicle-stimulating hormone

Pharmaceutical Biotechnology: Fundamentals and Applications, Fourth Edition

Volumn , Issue , 2013, Pages 277-283

  Sam, Tom ^a   de Leeuw, Renato ^a   Verheijden, Gijs ^b   Koole, Anneke ^c  

^a MSD   (Netherlands)

^b SYNTHON BV   (Netherlands)

^c Regulatory Affairs   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; GENETIC ENGINEERING;

ASSISTED REPRODUCTIVE TECHNOLOGIES; FOLLICLE STIMULATING HORMONE; IN-VITRO; INTRACYTOPLASMIC SPERM INJECTIONS;

PATIENT TREATMENT;

EID: 84956659001     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-6486-0_13     Document Type: Chapter

References (15)

1. De Leeuw R, Mulders J, Voortman G, Rombout F, Damm J, Kloosterboer L (1996) Structure-function relationship of recombinant follicle stimulating hormone (Puregon®). Mol Hum Reprod 2: 361-369
2. Devroey P, Boostanfar R, Koper NP, Jzerman PI, Mannaerts BMJL, Fauser BC, for the ENGAGE Investigators (2009) A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 24: 3063-3072 European Public Assessment Report Gonal-F (Follitropin alpha), CPMP/415/95, revision 18, 11-April 2011. European Agency for the Evaluation of Medicinal Products
3. European Public Assessment Report Gonal-F (Follitropin alpha), CPMP/415/95, revision 18, 11-April 2011. European Agency for the Evaluation of Medicinal Products
4. Fauser BCJM, Mannaerts BMJL, Devroey P, Leader A, Boime I, Baird DT (2009) Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update 15: 309-321
5. Fauser BCJM, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BMJL (2010) Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during controlled ovarian stimulation for in vitro fertilisation. Reprod Biomed Online 21: 593-601
6. Howles CM (1996) Genetic engineering of human FSH (Gonal-F®). Hum Reprod Update 2: 172-191
7. Mannaerts BMJL, De Leeuw R, Geelen J, Van Ravenstein A, Van Wezenbeek P, Schuurs A, Kloosterboer L (1992) Comparative in vitro and in vivo studies on the biological properties of recombinant human follicle stimulating hormone. Endocrinology 129: 2623-2630
8. Matzuk MM, Hsueh AJ, Lapolt P, Tsafriri A, Keene JL, Boime I (1990) The biological role of the carboxy-terminal extension of human chorionic gonadotropin (corrected) beta-subunit. Endocrinology 126: 376-383
9. Norman RJ, Zegers-Hochschild F, Salle BS, Elbers J, Heijnen E, Marintcheva-Petrova M, Mannaerts B (2011) Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Hum Reprod 26(8): 2200-2208
10. Olijve W, de Boer W, Mulders JWM, van Wezenbeek PMGF (1996) Molecular biology and biochemistry of human recombinant follicle stimulating hormone (PuregonR). Mol Hum Reprod 2: 371-382
11. Van Wezenbeek P, Draaier J, Van Meel F, Olyve W (1990) Recombinant follicle stimulating hormone. I. Construction, selection and characterization of a cell line. In: Crommelin DJA, Schellekens H (eds) From clone to clinic developments in biotherapy, vol I. Kluwer, Dordrecht, pp 245-251
12. Verbost P, Sloot WN, Rose UM, de Leeuw R, Hanssen RGJM, Verheijden GFM (2011) Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant. Eur J Pharmacol 651: 227-233
13. Voortman G, van de Post J, Schoemaker RC, van Gerwen J (1999) Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon®) by Pen-injector and syringe. Hum Reprod 14: 1698-1702
14. Mannaerts BMJL (2013) Innovative drug development for infertility therapy, Ph. D. thesis, Utrecht, The Netherlands, ISBN 978-90-393-5939-6
15. Seyhan A, Ata B (2011) The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist. Int J Womens Health 3: 243-255